Our results showing that IL4-DC from RR-MS patients respond to 1,25(OH)2D3 similarly to those of healthy subjects are in agreement with published data [64,65,66] which provided the rationale of using autologous DCs in MS treatment [16,67] and may contribute to reinforce this rationale. This evidence concerns the gene IL4 and myeloid sarcoma.